Zhang P, Zhou J, Feng F
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing.
Zhonghua Zhong Liu Za Zhi. 1995 Sep;17(5):365-7.
Twenty seven Patients with advanced breast cancer were treated with CAC (carboplatin, adriamycin, cyclophosphamide) regimen. Eighteen patients had no prior chemotherapy. Carboplatin was given 300 mg/m2 intravenously (IV), on day 1 or 150 mg/m2 on day 1, 2, adriamycin 40 mg/m2 IV on day 3, cyclophosphamide 500 mg/m2 IV on day 3, 10. The treatment was recycled every 28 days. The overall objective response was 63% (17/27) with a CR rate of 18% (5/27). The median duration of response was 9 months and median survival time was 17 months. The response rate of soft tissue metastasis was 61% (11/18). Lung metastasis responded in 3/5, liver metastasis in 3/3, pleura metastasis in 4/4, bone metastasis in 1/10. The response rate of previously untreated patients was 72% (13/18). The gastrointestinal reaction was mild. No renal toxicity was observed. Leukopenia (WHO grade II, III) was seen in 89%. These results indicate that CAC is an effective regimen for advanced breast cancer.
27例晚期乳腺癌患者接受了CAC（卡铂、阿霉素、环磷酰胺）方案治疗。18例患者既往未接受过化疗。卡铂在第1天静脉注射300mg/m²，或在第1天、第2天静脉注射150mg/m²，阿霉素在第3天静脉注射40mg/m²，环磷酰胺在第3天、第10天静脉注射500mg/m²。治疗每28天重复一次。总客观缓解率为63%（17/27），完全缓解率为18%（5/27）。中位缓解持续时间为9个月，中位生存时间为17个月。软组织转移的缓解率为61%（11/18）。肺转移3/5有反应，肝转移3/3有反应，胸膜转移4/4有反应，骨转移1/10有反应。既往未治疗患者的缓解率为72%（13/18）。胃肠道反应轻微。未观察到肾毒性。89%的患者出现白细胞减少（WHOⅡ级、Ⅲ级）。这些结果表明，CAC方案对晚期乳腺癌是一种有效的治疗方案。
